Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmonella Typhi Ty21a-based COVID-19 vaccine
- Development stage
- Preclinical
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A **Salmonella Typhi Ty21a-based COVID-19 vaccine** is an investigational oral vaccine concept in which the live-attenuated *Salmonella enterica* serovar Typhi strain Ty21a is engineered to carry a DNA construct encoding the SARS-CoV-2 spike protein or a portion of it. The intended mechanism is bacterial-vector delivery of a eukaryotic expression cassette to host tissues after oral administration, leading to spike antigen expression and induction of mucosal and systemic anti-SARS-CoV-2 immune responses. Based on available public information, this appears to be a preclinical or patent-disclosed vaccine platform rather than an approved product, and specific sponsor, clinical-stage, and manufacturing details are not clearly established from the cited public record.
- Other names
- novel salmonella-based coronavirus vaccineSalmonella Typhi Ty21a DNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Salmonella Typhi Ty21a-based COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salmonella Typhi Ty21a-based COVID-19 vaccine.